BMC Infectious Diseases (Oct 2012)

Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India

  • Ram Malathi,
  • Gupte Nikhil,
  • Nayak Uma,
  • Kinikar Aarti A,
  • Khandave Mangesh,
  • Shankar Anita V,
  • Sastry Jayagowri,
  • Bollinger Robert C,
  • Gupta Amita

DOI
https://doi.org/10.1186/1471-2334-12-282
Journal volume & issue
Vol. 12, no. 1
p. 282

Abstract

Read online

Abstract Background India has among the highest rates of infant malnutrition. Few studies investigating the growth patterns of HIV-exposed infants in India or the impact of timing of HIV infection on growth in settings such as India exist. Methods We used data from the Six Week Extended Nevirapine (SWEN) trial to compare the growth patterns of HIV-infected and HIV-exposed but uninfected infants accounting for timing of HIV infection, and to identify risk factors for stunting, underweight and wasting. Growth and timing of HIV infection were assessed at weeks 1, 2, 4, 6, 10, 14 weeks and 6, 9, 12 months of life. Random effects multivariable logistic regression method was used to assess factors associated with stunting, underweight and wasting. Results Among 737 HIV-exposed infants, 93 (13%) were HIV-infected by 12 months of age. Among HIV-infected and uninfected infants, baseline prevalence of stunting (48% vs. 46%), underweight (27% vs. 26%) and wasting (7% vs. 11%) was similar (p>0.29), but by 12 months stunting and underweight, but not wasting, were significantly higher in HIV-infected infants (80% vs. 56%, 52% vs. 29%, p Conclusion Baseline stunting and underweight was high in both HIV-infected and uninfected infants; growth indices diverged early and were impacted by timing of infection and SWEN prophylaxis. Early growth monitoring of all HIV-exposed infants is an important low-cost strategy for improving health and survival outcomes of these infants. Trial Registration NCT00061321

Keywords